Vyshak Venur, MD (@venurvyshak) 's Twitter Profile
Vyshak Venur, MD

@venurvyshak

Neuro-Oncologist | @UWMedicine | @FredHutch. Interested in clinical research in CNS tumors and metastases. Tweets are my own. #btsm

ID: 1178573477374128128

linkhttps://www.seattlecca.org/providers/vyshak-venur calendar_today30-09-2019 07:33:17

139 Tweet

367 Followers

803 Following

EANO (@eanoassociation) 's Twitter Profile Photo

One of the major unresolved questions in Neuro-Oncology: TMZ or PCV for grade 3 #oligodendrogliomas? Data from a retrospective national evaluation of 1596 first-line cases. academic.oup.com/nop/advance-ar… #btsm

Lynne P. Taylor, M.D. (@neulpt) 's Twitter Profile Photo

This paper was a product of the Ethics committee of the @AANMember. Grab an espresso @ 7 am Pacific time and join me in a discussion of legal physician-aid-in-dying. A complex and emotional topic.

Joshua Budhu (@joshuabudhu) 's Twitter Profile Photo

A reminder that when significant political or life events happen, it's ok to stop rounds and discuss, decompress, and reflect. Internalizing doesn't help

Manmeet Ahluwalia, MD, MBA, FASCO (@braintumordoc) 's Twitter Profile Photo

Thanks for the shout out PDBrown. Excited about preliminary results and looking forward to randomized phase 2 -SURVIVE currently enrolling! clinicaltrials.gov/ct2/show/NCT05… @platten_michael Michael Ciesielski @MimiVaxLLC Vyshak Venur, MD @nbutowski OncoAlert Journal of Clinical Oncology

Vyshak Venur, MD (@venurvyshak) 's Twitter Profile Photo

Finally a positive phase 3 study for patients with low grade glioma, who are often young at diagnosis.Will meaningfully delay chemo and RT! ⁦Lynne P. Taylor, M.D.⁩ ⁦Manmeet Ahluwalia, MD, MBA, FASCO⁩ ⁦Mustafa Khasraw (find me in BlueSky)⁩ ⁦MJ Lim-Fat⁩ ⁦Simon Lo⁩ ⁦ servier.us/serviers-pivot…

Manmeet Ahluwalia, MD, MBA, FASCO (@braintumordoc) 's Twitter Profile Photo

Ingo Mellinghoff Memorial Sloan Kettering Cancer Center presented Vorasidenib - oral inhibitor of IDH1 & 2 in low grade gliomas ASCO PFS benefit in Vorasidenib at 27.7 mth vs to 11.1 mth in placebo gp. Time to next treatment also increased. New option for low grade gliomas w IDH mutation! #ASCO2023

Ingo Mellinghoff <a href="/MSKCancerCenter/">Memorial Sloan Kettering Cancer Center</a> presented Vorasidenib - oral inhibitor of IDH1 &amp; 2 in low grade gliomas <a href="/ASCO/">ASCO</a> PFS benefit in Vorasidenib at 27.7 mth vs to 11.1 mth in placebo gp. Time to next treatment also increased. New option for low grade gliomas w IDH mutation! #ASCO2023
Dr. Tom Lynch (@hutchpresident) 's Twitter Profile Photo

I'm thrilled to welcome Dr. Sara Hurvitz to Fred Hutchinson Cancer Center and UW Department of Medicine. Sara is the right leader to bring together our hematology and oncology divisions, accelerate research and advance education with the goal of improving care for our patients. bit.ly/3Na2ut7

arjun sahgal (@sahgalarjun) 's Twitter Profile Photo

FANTASTIC review on leptomeningeal disease and thx Simon Lo for allowing Sunnybrook Health Sciences Centre to contribute with this all star international team pubmed.ncbi.nlm.nih.gov/37431225/

Binaytara (@binaytara) 's Twitter Profile Photo

Today the world observes Glioblastoma Awareness Day. At our conferences, we educate US cancer doctors on the latest care and treatments. Thank you, @venurvyshak, for insights on brain tumors at our recent Boise conference. Join us on our mission to bridge the cancer care gap.

Today the world observes Glioblastoma Awareness Day. At our conferences, we educate US cancer doctors on the latest care and treatments. Thank you, @venurvyshak, for insights on brain tumors at our recent Boise conference. Join us on our mission to bridge the cancer care gap.